MedTrace Logo

Analysis of Expression of Specific Markers in Hepatocellular Carcinoma

NCT00858000 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2009-12-24

No results posted yet for this study

Summary

Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out. This will be done retrospectively using available hepatocellular carcinoma tissue samples.

Conditions

Interventions

OTHER

Retrospective analysis of already archived samples

RNA extracted from tissue samples already archived

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00858000 on ClinicalTrials.gov